Dianthus Therapeutics Enters Material Definitive Agreement
Ticker: DNTH · Form: 8-K · Filed: Sep 11, 2025 · CIK: 1690585
| Field | Detail |
|---|---|
| Company | Dianthus Therapeutics, INC. /De/ (DNTH) |
| Form Type | 8-K |
| Filed Date | Sep 11, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $33.00, $32.999, $270.0 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-event
TL;DR
Dianthus Therapeutics signed a big deal, details to come.
AI Summary
Dianthus Therapeutics, Inc. announced on September 9, 2025, that it entered into a material definitive agreement. The company, formerly known as Magenta Therapeutics, Inc. until November 21, 2016, is incorporated in Delaware and its principal executive offices are located at 7 Times Square, New York, NY.
Why It Matters
This filing indicates a significant new development or contract for Dianthus Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing reports a material definitive agreement, but the specifics of the agreement and its potential impact are not yet disclosed, creating uncertainty.
Key Numbers
- 001-38541 — SEC File Number (Identifies the company's filing history with the SEC.)
- 81-0724163 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Dianthus Therapeutics, Inc. (company) — Registrant
- Magenta Therapeutics, Inc. (company) — Former name
- September 9, 2025 (date) — Date of earliest event reported
- 7 Times Square (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Dianthus Therapeutics?
The filing states that Dianthus Therapeutics entered into a material definitive agreement on September 9, 2025, but the specific details of this agreement are not provided in this current report.
When was Dianthus Therapeutics formerly known as Magenta Therapeutics, Inc.?
Dianthus Therapeutics was formerly known as Magenta Therapeutics, Inc. until November 21, 2016.
Where are Dianthus Therapeutics' principal executive offices located?
The principal executive offices of Dianthus Therapeutics are located at 7 Times Square, 43rd Floor, New York, New York, 10036.
What is the Standard Industrial Classification (SIC) code for Dianthus Therapeutics?
The Standard Industrial Classification code for Dianthus Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is September 9, 2025.
Filing Stats: 924 words · 4 min read · ~3 pages · Grade level 10.2 · Accepted 2025-09-11 07:20:07
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value DNTH The Nasdaq Capital M
- $33.00 — mon stock at a public offering price of $33.00 per share and, in lieu of common stock
- $32.999 — arrants") at a public offering price of $32.999 per share, which represents the per sha
- $270.0 m — iters, are expected to be approximately $270.0 million, after deducting the Underwriters
Filing Documents
- d96557d8k.htm (8-K) — 30KB
- d96557dex11.htm (EX-1.1) — 266KB
- d96557dex41.htm (EX-4.1) — 65KB
- d96557dex51.htm (EX-5.1) — 8KB
- g96557g0910115836900.jpg (GRAPHIC) — 2KB
- 0001193125-25-200715.txt ( ) — 579KB
- dnth-20250909.xsd (EX-101.SCH) — 3KB
- dnth-20250909_lab.xml (EX-101.LAB) — 18KB
- dnth-20250909_pre.xml (EX-101.PRE) — 11KB
- d96557d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. EXHIBIT INDEX Exhibit No. Description 1.1 Underwriting Agreement, dated as of September 9, 2025, by and among Dianthus Therapeutics, Inc., Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., and Stifel, Nicolaus & Company, Incorporated 4.1 Form of Pre-Funded Warrant 5.1 Opinion of Gibson, Dunn & Crutcher LLP 23.1 Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DIANTHUS THERAPEUTICS, INC. Date: September 11, 2025 By: /s/ Adam M. Veness, Esq. Adam M. Veness, Esq. SVP, General Counsel and Secretary